CELL IMPACT AB (PUBL) Financials Cell Impact AB (publ) Nasdaq Stockholm
Equities
CI
SE0005003217
Industrial Machinery & Equipment
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.13 SEK | +4.00% |
|
-12.04% | -42.22% |
| Apr. 26 | Cell Impact AB Signs Agreement Valued At SEK 3.2 Million | CI |
| Apr. 25 | Cell Impact AB Announces Board and Committee Changes | CI |
Valuation
| Fiscal Period: Dezember | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 71.24 | 395 | 1,892 | 2,020 | 830.3 | 133.1 |
| Enterprise Value (EV) 1 | 75.53 | 379.4 | 1,762 | 2,011 | 710.3 | 75.93 |
| P/E ratio | -1.49 x | -5.95 x | -41.5 x | -19.8 x | -7.96 x | -0.2 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 10.9 x | 33 x | 64.6 x | 24.7 x | 9.07 x | 2.79 x |
| EV / Revenue | 11.5 x | 31.7 x | 60.1 x | 24.6 x | 7.76 x | 1.59 x |
| EV / EBITDA | -1.8 x | -8.55 x | -45.3 x | -27.8 x | -7.65 x | -0.7 x |
| EV / FCF | -2.18 x | -10.8 x | -33.2 x | -18.3 x | -5.22 x | -0.72 x |
| FCF Yield | -45.9% | -9.23% | -3.02% | -5.48% | -19.2% | -140% |
| Price to Book | 3.72 x | 8.68 x | 10.6 x | 14.2 x | 2.56 x | 0.44 x |
| Nbr of stocks (in thousands) | 18,128 | 45,929 | 51,842 | 75,654 | 75,827 | 591,450 |
| Reference price 2 | 3.930 | 8.600 | 36.50 | 26.70 | 10.95 | 0.2250 |
| Announcement Date | 3/15/19 | 3/20/20 | 3/26/21 | 3/25/22 | 3/24/23 | 3/22/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Dezember | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 6.564 | 11.96 | 29.31 | 81.8 | 91.53 | 47.66 |
| EBITDA 1 | -41.93 | -44.4 | -38.93 | -72.3 | -92.9 | -108.1 |
| EBIT 1 | -44.64 | -47.48 | -43.06 | -78.04 | -104.1 | -119.5 |
| Operating Margin | -680.02% | -396.9% | -146.9% | -95.4% | -113.71% | -250.7% |
| Earnings before Tax (EBT) 1 | -44.57 | -48.4 | -44.26 | -79.73 | -104.1 | -121.4 |
| Net income 1 | -44.57 | -48.4 | -44.26 | -79.85 | -104.2 | -121.4 |
| Net margin | -679% | -404.59% | -151% | -97.62% | -113.86% | -254.71% |
| EPS 2 | -2.644 | -1.446 | -0.8794 | -1.349 | -1.376 | -1.107 |
| Free Cash Flow 1 | -34.68 | -35.04 | -53.15 | -110.2 | -136.1 | -106.2 |
| FCF margin | -528.24% | -292.86% | -181.36% | -134.69% | -148.73% | -222.81% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/15/19 | 3/20/20 | 3/26/21 | 3/25/22 | 3/24/23 | 3/22/24 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 4.29 | - | - | - | - | - |
| Net Cash position 1 | - | 15.6 | 130 | 9.05 | 120 | 57.1 |
| Leverage (Debt/EBITDA) | -0.1022 x | - | - | - | - | - |
| Free Cash Flow 1 | -34.7 | -35 | -53.2 | -110 | -136 | -106 |
| ROE (net income / shareholders' equity) | -211% | -151% | -35.8% | -46.4% | -44.6% | -38.7% |
| ROA (Net income/ Total Assets) | -82.5% | -61.7% | -17.9% | -20.3% | -20.3% | -19.1% |
| Assets 1 | 54.03 | 78.38 | 247.5 | 394.2 | 512.9 | 636.8 |
| Book Value Per Share 2 | 1.060 | 0.9900 | 3.430 | 1.890 | 4.280 | 0.5100 |
| Cash Flow per Share 2 | 0.4400 | 0.3700 | 2.580 | 0.3800 | 2.170 | 0.1700 |
| Capex 1 | 8.65 | 12.5 | 22 | 53 | 62.4 | 48.8 |
| Capex / Sales | 131.76% | 104.75% | 75.21% | 64.76% | 68.22% | 102.36% |
| Announcement Date | 3/15/19 | 3/20/20 | 3/26/21 | 3/25/22 | 3/24/23 | 3/22/24 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +54.30% | 3.74B | |
| +8.22% | 2.04B | |
| +0.43% | 1.99B | |
| -6.79% | 1.91B | |
| -5.37% | 1.38B | |
| +15.70% | 1.36B | |
| -16.05% | 1.38B | |
| -28.65% | 1.3B | |
| -17.02% | 1.24B |
- Stock Market
- Equities
- CI Stock
- CI Stock
- Financials Cell Impact AB (publ)
